Background: CD30 is a member of TNF receptor family and expressed on lymphocytes and other hematopoietic cells following activation as well as Hodgkin and ReedSternberg cells in Hodgkin's lymphoma. In this study, CD30-mediated regulation of cell adhesion molecule expression on normal activated mouse T cells was investigated. 
Introduction
CD30 belongs to tumor necrosis factor (TNF)/ nerve growth factor (NGF) receptor superfamily (1, 2) and was originally discovered on Hodgkin and Reed-Sternberg cells in Hodgkin's lymphoma (3) . It is now known as an activation antigen that is expressed on normal T an B lymphocytes following antigenic or mitogenic stimulation (2) (3) (4) (5) .
Studies with human T cell clones revealed CD30 to be preferentially expressed by Th2 clones (4, 5) and CD30 signaling induces Th2 differentiation (6) . Consequently, despite several controversial reports (7, 8) , CD30 has long been proposed as a marker of type 2 helper T (Th2) cells. After commitment, only Th2 cells express CD30 but not Th1 (9) and CD30 expression is regulated by cytokines in a very similar fashion to Th2 differentiation. For instances, CD30 expression is upregulated by IL 4 and downregulated by IFN (9) , which are critical cytokines for Th2 and Th1 differentiation, respectively. Furthermore, CD28 stimulation is responsible for CD30 expression (10) and also differentiation of Th2 rather than Th1 cells (11, 12) through acceleration of IL 4 receptor sensitivity (13) . These data strongly implicate that CD30 may play an important role in Th2 differentiation.
At a clonal level, CD30 signaling have shown pleiotropic and controversial effects depending on cell types. Binding of CD30 ligand (CD30 L) to its receptor induces apoptosis (14) (15) (16) and also enhances cell proliferation (10, 14, 17) . Antibody production of murine B cell can be enhanced by CD30 ligation (18) , however, similar effects on human B cells could not be observed (19) . CD30 functions also include NF-B activation (20) , cytokine production (21) , and inhibition of cytotoxicity of NK cell line through downregulation of CD28 expression (22) . CD30-deficient mice showed partial defect in negative selection of thymus cells (23) and these findings have been confirmed by the experiments with CD30 transgenic mice (24) that CD30 overexpression enhances negative selection in the thymus. Another observation that transferred autoreactive T cells without CD30 proliferate extensively in vivo and can cause substantial tissue damage (25) strongly suggest the involvement of CD30 in the onset of autoimmune disease. CD30 has also attracted much interest as a possible parameter defining subgroups of leukemia (26) , lymphoma (27, 28) . The plausible relevance of CD30 to AIDS pathogenesis was also proposed (29) . However, despite lots of studies, the functional role of CD30 under physiological condition remains unclarified so far.
It has been reported that CD30 induces homotypic cell aggregation of cell lines (22) , which was not blocked by antibodies to LFA-1, ICAM-1, CD2, LFA-3 or CD29 (22) . Although it was shown that CD30 ligand enhanced ICAM-1 expression of Hodgkin and Reed-Sternberg (H-RS) cells (30) , such role of CD30 in normal lymphocytes has not been addressed. In this study, CD30-mediated ICAM-1 regulation and its mechanisms were investigated in normal activated T cells. Additionally, such regulatory role of CD30 was also explored for the several kinds of cell adhesion molecules expressed on murine T cells.
Materials and Methods
Mice and cells. Balb/c mice were supplied from SamTaco (Osan, Korea) and maintained in an environmental controlled rearing system at Jeonju University. After mice were sacrificed by cervical dislocation, peripheral and mesenteric LN cells were prepared and pooled for simulation. Purified T cells were obtained by plastic adherence and subsequent negative selection using MACS and anti-B220-coated microbeads (Miltenyi, Germany). After partial removal of non-adherent T cells following plastic adherence, attached B-enriched spleen cells were used for antigen-presenting cells (APC), which were treated with 50 g/ml of mitomycin C for 15 min prior to use and washed 4 times with IMDM containing 5% FBS. Antibodies, cytokines and reagents. Anti-CD3, and hamster anti-mouse CD30 (26) 5 cells/ml. After 2 days of incubation, culture plates were shaken at low speed on a voltex mixer for 5 seconds and non-adherent cells were removed by aspiration. The wells were subsequently washed 2 times with prewarmed medium. MTT (Sigma, 2 mg/ml) was added for 4 hrs and formazan crystal was solubilized with acid isopropyl alcohol. Absorbance was determined at 550 nm. Statistics. Results were analyzed by Student's t test for comparison between two groups and p values 0.05 were accepted as the level of significance.
Results
Longer time period of stimulation is required for CD30 expression than for proliferation. For functional assay of CD30, its expression should be induced by antigenic or mitogenic stimulation since naive cells usually exhibit no or very little, if any, expression of CD30 and high level of CD30 expression is prerequisite for enough CD30 signal. In this study, purified T cells were stimulated with immobilized anti-CD3 at 1×10 6 cells/ml). However, at day 3 of stimulation, CD30 expression was much lower than at day 5 (MFI, 5 vs 15, Fig. 1B and 1C) . It suggests that relatively prolonged stimulation is required for CD30 expression, when compared to cell proliferation.
Change of T cell adhesion by cross-linking of CD30.
Cross-linking of CD30 did not modulate cell proliferation of normal activated T cells in this study (data not shown). Instead, cells were likely to adhere so firmly to the surface that adherence was tested following cross-linking of CD30. Stimulated cells were harvested and CD30 was cross-linked with immobilized anti-CD30 antibody for 2 days and then their adherence to surface was examined. As shown in Fig. 2 , immobilized hamster IgG did not affect T cell adhesion whereas anti-CD30 drastically enhanced the adherence from 0.22 to 0.72 0.88 of OD by Non-stimulated T cells showed the constitutive but low expression of ICAM-1 as on naive T cells (Fig. 3A) . However, its expression was markedly upregulated by CD3 stimulation (Fig. 3B) . Following induction of CD30 expression by stimulation of T cells for 5 days, CD30 on the activated T cells was cross-linked by anti-CD30 antibody or control hamster IgG for further 1 day. Those cells were harvested and stained with antibodies to several adhesion molecules that might be expressed on T cells. As shown in Fig. 3C , and 3d, CD30 signaling considerably enhanced ICAM-1 (Fig. 3C ) and, to a lesser extent, CD102 (ICAM-2) expression (Fig. 3D) . Repeated experiments showed that these expressional regulations were statistically significant (p 0.01 or p 0.05, respectively; Fig. 4 ). The regulatory function of CD30 was also investigated for other adhesion molecules including CD2, and CD18. However, the expression of CD2 was not affected by CD30 signaling, and slightly lower expression of CD18 was observed after cross-linking of CD30, although the decrement was not significant (Fig. 4) .
Inability of cytokines to enhance ICAM-1 expression. Several cytokines have been documented as regulators for ICAM-1 expression like IL 4, TNF and IFN (31).
Therefore, these cytokines were tested for their regulatory functions on ICAM-1 expression of lymph node T cells. As shown in Fig. 5 , the results showed 
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that all of these cytokines could not enhance ICAM-1 expression (Fig. 5B-D ) and culture supernatant prepared by CD30 signaling also contained no regulatory factors (data not shown).
Contribution of NF-B activation to CD30-mediated upregulation of ICAM-1 expression.
It has been reported that CD30 signals activates NF-B (20) and which is related to ICAM-1 expression (32). These previous results thus leaded to a hypothesis that CD30 activates NF-B and which in turn, upregulates ICAM-1 expression. In this study, NF-B inhibitor, PDTC was added to confirm whether it might block CD30-mediated enhancement of ICAM-1 expression.
As summarized in Table I , 0.1 mM PDTC significantly reduced ICMA-1 expression induced by immobilized anti-CD30 (MFI, 44 24) to a control level (MFI, 22) with control IgG. In other words, CD30-mediated enhancement of ICAM-1 expression was mostly abrogated by NF-B inhibitor, whereas it did not affect both of CD2 and CD102 expression. This differential outcome strongly supports that NF-B activation contributes to CD30-mediated ICAM-1 regulation and additionally CD30-mediated ICAM-1 regulation is by no means a default response of cellular activation.
Discussion
CD30 expression requires prior activation like TCR ligation or mitogenic stimulation. In this study, CD30 function was investigated focusing on T cells using purified lymph node T cells and anti-CD3 antibody. Firstly, it was observed that primary stimulation for 3 days induces low level of CD30 even with strong mitogen, plate-bound anti-CD3 in combination with exogenous IL 4 added during primary stimulation, which leaded to high cell proliferation from 1×10 6 cells/ml to 1.6×10 6 cells/ ml for 3 days. In this study, prolonged stimulation 
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: added at 0.1 mM, : representative data were presented from 2 separate experiments with similar results protocol for 5 days was also evaluated for induction of CD30. The data shown in Fig. 1B, and 1C clearly indicate that longer time period may require for CD30 expression than only for cell proliferation. One possible explanation for this finding is that CD30 expression is not induced only by antigenic stimulation but also require another factors such as, IL 4 (9,10) or CD28 costimulatory signal (10) and which would be provided more abundantly at later stage of stimulation.
Using cultured cell lines, several investigators reported that CD30 enhances cell proliferation or induces apoptosis (14) (15) (16) (17) . However, in this study, ligation of CD30 alone altered neither cell proliferation nor apoptosis of normal activated LN cells (data not shown). It suggests that CD30 signaling effect is variable depending on cell types, antigenic stimulation or other undefined factor(s). Instead, cross-linking of CD30 appeared to induce stronger adherence to the surface on which anti-CD30 was immobilized. This observation was followed by investigation of expressional change of cell adhesion molecules expressed on T cells. CD18 highly expressed on T cells was not altered. In contrast, the data presented here apparently showed that CD30 signaling upregulates ICAM-1 and, to a lesser extent, ICAM-2 expression (Fig. 3) . It is also supportive to above results that cross-linking of CD30 induces much higher level of soluble ICAM-1 secretion than control antibody (data in preparation). Expression of ICAM-1 on T cells is constitutive but relatively low (Fig. 3A) . By CD3 stimulation, its expression considerably increased and subsequently diminished again without stimulating signal (data not shown). CD30 signaling is likely somehow to provide the activation state enough to sustain ICAM-1 production. However, identification of the CAM directly responsible for CD30-mediated adhesion awaits more studies because ICAM-1 expression is unlikely to participate in T cell adhesion to substrate.
Proinflammatory cytokines such as TNF , and IFN and T-cell derived IL 4 are well known regulatory molecules for activation (33) (34) (35) and ICAM-1 expression (31, 36, 37) in endothelial cells, and other types of cells including fibroblasts (38) , mast cells (39), glioblastoma cells (40) , and astrocytes (41) . Thus, it was examined if these cytokines might be engaged in CD30-mediated enhancement of ICAM-1 expression. The results showed that activated T cells did not respond to none of these exogenously added cytokines in ICAM-1 expression (Fig. 5) . These results are not likely to be due to absence of cytokine receptors. Instead, these results suggest that lymphoid cells have a distinct pathway from endothelial cells at the downstream of cytokine binding with cell surface cytokine receptor. Piela-Smith et al. (42) have also suggested that those cytokines exert variable effects on modulation of ICAM-1 expression depending on target cell types. In this study, direct assay for CD30-mediated NF-B activation was not repeated because it was already observed (20) . However, inhibition of CD30-mediated enhancement of ICAM-1 expression by NF-B inhibitor (Fig. 6) clearly demonstrated that CD30 upregulates ICAM-1 expression through NF-B activation. Furthermore, addition of PDTC did not affect the CD2 and CD102 expression, indicting that such PDTC effect did not result from non-specific inhibition of T cell activation. NF-B is involved in T cell activity such as proliferation, synthesis of cytokines and its receptors (43) , and replication of human immunodeficiency virus (HIV) (44) . Upregulaton of ICAM-1 expression might be one of the several phenomena resulted from NF-B activation by CD30 signaling. Besides ICAM-1 regulation, CD30 may exert many other functions through ubiquitous transcription factor, NF-B pathway.
Functional significance of CD30 regulation for ICAM-1 expression on T cells was not fully elucidated in this study. ICAM-1 is a cell surface glycoprotein of immunoglobulin superfamily that has been known to mediate various cell-cell interactions, including leukocyte adhesion to vascular endothelial cells, as well as cytotoxicity, tumor progression, and metastasis (reviewed in Ref. Finally, cell adhesion molecules can help the primary signaling between two interacting cells by augmentation of contact. Accordingly, the effects of CD30 signal may appear variably depending upon the feature of primary signals, although we also cannot rule out the involvement of the signals directly transduced by counterpart molecules.
